Side by side
Liraglutide vs SLU-PP-332
Both are discussed for weight loss. What this site records about each, side by side. Every figure is on the compound's own page with the source it came from.
| Liraglutide | SLU-PP-332 | |
|---|---|---|
| What it is | The first GLP-1 analogue approved for weight loss. A daily injection, superseded by weekly semaglutide but still the best-documented compound in the class. | A mouse compound that got a press release. It reproduced some effects of endurance training in mice, and no human has ever taken it. |
| EvidenceHow much human evidence exists, not how well it works. | Approved | Preclinical |
| Regulatory statusReviewed 2026-08-16 | Approved by the FDA and EMA. Marketed as Victoza for type 2 diabetes and as Saxenda for chronic weight management at a higher dose. Both carry a boxed warning about thyroid C-cell tumours. Compounded or research-chemical liraglutide is not the approved product and has not been through the manufacturing controls the approval rests on. | Not approved anywhere and not in human trials. An academic research compound sold as a research chemical, typically as a powder with no pharmaceutical manufacturing behind it. |
| Routes | Subcutaneous | Oral, Subcutaneous |
| Half-life | 13 hours | Not recorded |
| Cheapest per mgVials only, read from vendors' own listings and dated on the price index. | Not recorded | $1.00/mg |
| Median per mg | Not recorded | $13.41/mg |
| Vendors with a price | Not recorded | 12 |
| Storage once mixed | After first use, up to 30 days at room temperature below 30 °C or refrigerated. Protect from light and do not freeze. | A small molecule, not a peptide. Solvent choice varies, and vendors rarely say what theirs is. |
Compare two other compounds · The full price index
This page is educational. It describes what published research reports, not what you should do. Peptides discussed here are largely not approved for human use, and nothing on BioAlmanac is medical advice. Nothing here ranks these two against each other. A table can show that one has more human evidence behind it or costs less per milligram; neither of those is a recommendation, and the right comparison for any person is one their doctor makes with them.